Longevity Evidence Lab Human evidence, uncertainty intact
Research interpretation, not diagnosis or personal treatment advice. Urgent symptoms belong with a clinician, not a browser tab.
Home / Evidence / Rapamycin / sirolimus
Prescription medicine research

Rapamycin / sirolimus

Exceptional animal lifespan evidence; no proof of human life extension and meaningful clinical risks.

The 30-second verdict Rapamycin is among the most reproducible pharmacological lifespan interventions in laboratory animals. In humans it is a prescription immunosuppressive medicine with recognised adverse effects and interactions. Small ageing-related trials test immune, skin, periodontal or functional endpoints, but there is no evidence that self-medication extends human life.

Evidence matrix

These scores describe different evidence domains. A strong mechanism cannot compensate for missing human outcomes, and a useful clinical effect need not imply slower biological ageing.

Human clinical outcomes Preliminary
Human biomarkers Limited
Animal lifespan Strong
Mechanistic plausibility Strong
Safety certainty Moderate
Direct longevity relevance Preliminary

What has been shown in humans?

Human research is early, heterogeneous and generally uses surrogate or organ-specific outcomes. The evidence base is not sufficient to establish a preventive regimen for healthy people.

What remains uncertain?

Dose schedule, risk-benefit balance in healthy adults, infection and metabolic effects, monitoring requirements, duration and effects on disability or mortality are unresolved.

Doses used in research

Descriptive, not prescriptive No dose is presented here. Prescription and experimental regimens require clinical oversight and cannot be inferred safely from animal studies or online protocols.

Safety and interpretation

  • Known risks include mouth ulcers, infection, impaired wound healing, lipid changes, blood-count abnormalities and numerous medicine interactions.
  • This site does not support unsupervised use or sourcing prescription products outside normal medical care.
  • Animal longevity evidence is scientifically important but does not cancel human pharmacology.

Primary sources and evidence reviews

Editorial note

This dossier was last reviewed on 13 July 2026. Ratings can change when larger trials, adverse-event data or better systematic reviews appear. Corrections should alter the page rather than being buried in a social-media thread.